Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News

    Latest News - Page 101

    Shilpa Medicare gets 5 USFDA observations for Raichur facility

    Shilpa Medicare gets 5 USFDA observations for Raichur facility

    Medical Dialogues Bureau31 July 2019 9:30 AM IST
    "We have received Form 483 with five observations, with no repeat observations and any data integrity observations. The observations are mostly...
    Dr Reddys unveils generic version of Lyrica capsules in US for treating neuropathic pain

    Dr Reddy's unveils generic version of Lyrica capsules in US for treating neuropathic pain

    Medical Dialogues Bureau31 July 2019 9:16 AM IST
    Dr Reddy's Labs' Pregabalin capsule is a generic version of C P Pharmaceuticals International C V's Lyrica capsules which had US sales of around...
    Piramal Enterprises Q1 profit rises 21 percent to Rs 461 crore

    Piramal Enterprises Q1 profit rises 21 percent to Rs 461 crore

    Medical Dialogues Bureau31 July 2019 9:00 AM IST
    Piramal Enterprises said its total loan book grew 20 per cent year-on-year to Rs 56,605 crore. The housing finance loan book, which constitutes 11 per...
    NeuroVives NeuroSTAT Project Receives USFDA Fast Track Designation

    NeuroVive's NeuroSTAT Project Receives USFDA Fast Track Designation

    Medical Dialogues Bureau30 July 2019 2:20 PM IST
    NeuroVive Pharmaceutical AB announced that the company's candidate drug NeuroSTAT, in development for treatment of moderate to severe traumatic brain...
    Cipla Gulf, Alvotech partner to commercialise AVT02 Biosimilar of AbbVies Blockbuster drug Humira

    Cipla Gulf, Alvotech partner to commercialise AVT02 Biosimilar of AbbVie's Blockbuster drug Humira

    Medical Dialogues Bureau30 July 2019 1:15 PM IST
    Mumbai: Biopharmaceutical company Alvotech and Cipla Gulf FZ LLC ("Cipla Gulf"), a wholly-owned subsidiary of the leading global pharmaceutical...
    Strides Pharma inks JV pact with Chinas Sihuan Pharma

    Strides Pharma inks JV pact with China's Sihuan Pharma

    Medical Dialogues Bureau30 July 2019 12:47 PM IST
    China: Strides Pharma Science said on Monday it has entered into a joint venture with China's Sihuan Pharmaceutical Holdings Group with a view to fast...
    Granules India completes USFDA inspection for Bonthapally facility with one observation

    Granules India completes USFDA inspection for Bonthapally facility with one observation

    Farhat Nasim29 July 2019 10:00 AM IST
    Granules India Ltd's Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plant by volume. New Delhi: Drug...
    Cipla arm, Alvotech enter partnership for commercialization of adalimumab biosimilar AVT02

    Cipla arm, Alvotech enter partnership for commercialization of adalimumab biosimilar AVT02

    Medical Dialogues Bureau29 July 2019 9:45 AM IST
    Under the partnership, Alvotech will be responsible for the development and supply of AVT02, an adalimumab biosimilar, while Cipla Gulf will be...
    Pfizer, Mylan in talks to merge off-patent drugs business

    Pfizer, Mylan in talks to merge off-patent drugs business

    Medical Dialogues Bureau29 July 2019 9:30 AM IST
    Mylan shareholders would receive a little more than 40 per cent of the newly formed entity, with Pfizer shareholders receiving the remainder, the...
    Novartis CEO Vas Narasimhan vows not to sell Sandoz generics unit

    Novartis CEO Vas Narasimhan vows not to sell Sandoz generics unit

    Medical Dialogues Bureau29 July 2019 9:17 AM IST
    Novartis is revamping Sandoz, a process Narasimhan has previously said will take roughly the next year and a half. He has already sold a generic U.S....
    Alkem Labs Founder Samprada Singh passes away at the age of 92 years

    Alkem Labs Founder Samprada Singh passes away at the age of 92 years

    Medical Dialogues Bureau29 July 2019 9:00 AM IST
    Patna: Mumbai-based drugmaker, Alkem Laboratories Founder and Chairman Emeritus, Samprada Singh expired on Saturday at the age of 92 years after a...
    Jubilant Life Sciences net profit slips 7.68 percent to Rs 185 crore for June quarter

    Jubilant Life Sciences net profit slips 7.68 percent to Rs 185 crore for June quarter

    Farhat Nasim29 July 2019 9:00 AM IST
    "We have had a steady performance during the quarter. Pharmaceutical segment revenues have been higher by 12 per cent YoY led by growth in CMO,...
    PrevNext

    Popular Stories

    Suven Life Sciences Q2 revenue up 39pc to Rs 280 crore

    Suven Life Sciences Q2 revenue up 39pc to Rs 280 crore

    Lasa Supergenerics gets FDA nod for Progesterone

    Lasa Supergenerics gets FDA nod for Progesterone

    Biocon names Siddharth Mittal as new CEO, Joint MD; bids farewell to Arun Chandavarkar

    Biocon names Siddharth Mittal as new CEO, Joint MD; bids farewell to Arun Chandavarkar

    Coronavirus Update: Sanitizers, surgical masks, n95 masks, gloves brought under Essential Commodities Act

    Coronavirus Update: Sanitizers, surgical masks, n95 masks, gloves brought under Essential...

    Supreme Court to hear PIL seeking direction to govt for banning unregulated medical devices

    Supreme Court to hear PIL seeking direction to govt for banning unregulated medical devices

    China offers tariff exemptions on US medical equipment amid virus outbreak

    China offers tariff exemptions on US medical equipment amid virus outbreak

    Mediclaim cannot be denied on presumption of pre-existing disease: NCDRC

    Mediclaim cannot be denied on presumption of pre-existing disease: NCDRC

    Coronavirus: CDSCO issues guidelines to be followed while visiting CDSCO office.

    Coronavirus: CDSCO issues guidelines to be followed while visiting CDSCO office.

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok